Ruckdeschel heads cancer institute at University of Mississippi Medical Center

Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print

John Ruckdeschel was named director of the cancer institute of the University of Mississippi Medical Center as well as Ergon Chair in Cancer Research.

Ruckdeschel, who previously served as the director of the Moffitt Cancer Center, led that institution to NCI Comprehensive Cancer Center designation and to become the third largest clinical cancer program in the U.S.

He then moved to the Barbara Ann Karmanos Cancer Center in Detroit where he re-acquired its NCI comprehensive status and completed the process of making Karmanos a freestanding cancer hospital.

His research was originally in basic immunology but gravitated to clinical and translational research in thoracic malignancies. Ruckdeschel’s career has focused on lung cancer and other thoracic malignancies. He is credited with more than 150 peer reviewed manuscripts and co-editorship of the Textbook of Thoracic Oncology. He is a North American Editor for the Cochrane Lung Cancer Review Group.

Ruckdeschel and Terrance Albrecht co-developed a means to effectively video record patient-physician interactions and applied this technology to understanding clinical trials accrual and end of life decision-making.

YOU MAY BE INTERESTED IN

Shearwood McClelland III’s grandfather was a ditchdigger who dreamed that his six Black daughters would become doctors. McClelland’s mother did not disappoint—she became the first Black woman board-certified in maternal fetal medicine in the history of the United States.  Now, McClelland is the chief medical officer of Cancer Health Equity at the University of Oklahoma...

As oncology enters a new era of precision medicine, the Food and Drug Administration’s evolving biomarker strategy aims to ensure that life-saving therapies are tailored to individual patient needs, fostering safer and more effective treatments.  Historically, therapies were approved with broad indications based on overall efficacy, even when outcomes for biomarker-positive and -negative patients were...

In the evolving landscape of pediatric oncology, survivorship research has become an essential component of our mission to improve long-term patient outcomes. At City of Hope, we are focused on not only curing childhood cancers but also ensuring that survivors live the healthiest lives possible. A significant part of my research has been dedicated to mitigating the long-term toxicities of cancer therapy—particularly cardiovascular complications that can arise decades after treatment.

Never miss an issue!

Get alerts for our award-winning coverage in your inbox.

Login